Literature DB >> 6153225

Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.

B M Lewis, R Izbicki.   

Abstract

Forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) studies in two patients with proved interstitial fibrosis after low doses of bleomycin were contrasted with these measurements in 21 patients who received bleomycin without toxicity. The FVC decreased significantly (20% or more) in both fibrosis patients and in seven others. In one fibrosis patient and in three others the results could be explained by weakness. The DLco fell in both patients with fibrosis and in 12 others. Correction for decrease in hemoglobin level accounted for the change in one of the toxic patients and seven of the others, but hemoglobin correction made two insignificant changes significant and increased therapy values above control four times. Since these tests have many false-positive results and can be affected by weakness and anemia leading to false-negative results their use is ineffective and may be misleading.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153225

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

1.  Bleomycin lung: a case report.

Authors:  Rabia Sofia Rashid
Journal:  BMJ Case Rep       Date:  2009-04-14

Review 2.  The correlation of lung structure with function.

Authors:  N Berend
Journal:  Lung       Date:  1982       Impact factor: 2.584

3.  The single-breath carbon monoxide transfer test 25 years on: a reappraisal. 2--Clinical considerations.

Authors:  C Ogilvie
Journal:  Thorax       Date:  1983-01       Impact factor: 9.139

4.  Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy.

Authors:  O Ugur; B Caner; M D Balbay; H A Ozen; D Remzi; N Ulutuncel; C Bekdik
Journal:  Eur J Nucl Med       Date:  1993-02

5.  The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy.

Authors:  Takeshi Kinjo; Koji Tomaru; Diana C Haines; Dennis M Klinman
Journal:  Respir Res       Date:  2012-06-18

6.  Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

Authors:  N S Stuart; C M Woodroffe; R Grundy; M H Cullen
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

Review 7.  Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Authors:  Robert A Watson; Hugo De La Peña; Maria T Tsakok; Johnson Joseph; Sara Stoneham; Jonathan Shamash; Johnathan Joffe; Danish Mazhar; Zoe Traill; Ling-Pei Ho; Sue Brand; Andrew S Protheroe
Journal:  Br J Cancer       Date:  2018-10-25       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.